Activation of fibrynolysis in children with chronic B or C hepatitis;Aktywacja układu fibrynolizy u dzieci chorych na przewlekłe wirusowe zapalenie wa̧troby typu B lub typu C

Polski Merkuriusz Lekarski

Volumn 17, Issue 100, 2004, Pages 316-320

  Michalska, Kinga ^a   Szaflarska Popławska, Anna ^a   Dymek, Grazyna ^a   Kotschy, Maria ^a  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

Children; Fibrinolysis; HBV; HCV

Indexed keywords

ALPHA 2 ANTIPLASMIN; FIBRINOGEN; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADOLESCENT; ARTICLE; CELIAC DISEASE; CHRONIC HEPATITIS; FEMALE; FIBRINOLYSIS; GLUTEN FREE DIET; HEPATITIS B; HEPATITIS C; HISTOPATHOLOGY; HUMAN; INFLAMMATION; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; SCHOOL CHILD; THROMBOCYTE POOR PLASMA;

ADOLESCENT; ANTIFIBRINOLYTIC AGENTS; ANTIPLASMIN; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOGEN; FIBRINOLYSIS; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; MALE; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLAND; TISSUE PLASMINOGEN ACTIVATOR;

EID: 9144234142     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Aleman-Valls M.R. i wsp.: Lack of relationship between plasma thrombomodulin and portal hypertension in alcoholic liver disease. Alcohol., 2000, 20, 205-206.
2. Baker E.A, Leaper D.J.: Proteinases, their inhibitors, and cytokine profiles in acute wound fluid. Wound Repair, Regen., 2000, 8, 392-398.
3. Becker B.F. i wsp.: Endothelial function and hemostasis. Z. Kardiol., 2000, 89, 160-167.
4. Ben-Ari Z: i wsp.: Disseminated intravascular coagulation in liver cirrhosis, fact or fiction? Am. J. Gastroenterol., 1999, 94, 2977-2982.
5. Bueno M.R., Daneri A., Armendariz-Borunda J.: Cholestasis-induced fibrosis is reduced by interferon alpha-2a and is associated with elevated liver metalloprotease activity. J. Hepatol., 2000, 33, 915-925.
6. Cheema S.P. i wsp.: Mediators of fibrinolysis in orthotopic liver transplantation. Clin. Transplant., 1996, 10, 24-27.
7. Czerwionka-Szaflarska M., Pawłowska M., Halota W.: Level of selected cytokines (IL-1 beta, IL-2, IL-4, IL-6) in patients with chronic hepatitis type B and type C. Int. Rev. Allergol. Clin. Immunol., 1996, 2, 80-82.
8. De Moliner L: i wsp.: Serum and liver HCV-RNA levels in patients with chronic hepatitis C, correlation with clinical and histological features. Gut, 1998, 42, 856-860.
9. Di Bisceglie A.M., Hoofnagle J.H., Krawczynski K.: Changes in hepatitis C virus antigen in liver with antiviral therapy. Gastroenterology, 1993, 105, 858-862.
10. Fitch P. i wsp.: Distribution of plasminogen activator inhibitor in normal liver, cirrhotic liver, and liver with metastases. J. Clin. Pathol., 1994, 47, 218-221.
11. Galun E. i wsp.: Human interleukin-6 facilitates hepatitis B virus infection in vitro and in vivo. Virology, 2000, 270, 299-309.
12. Hayashi T: i wsp.: Plasma from patients with cirrhosis increases tissue plasminogen activator release from vascular endothelial cells in vitro. Liver, 1998, 18, 186-190.
13. Heiden M., Seitz R., Egbring R.: The role of inflammatory cells and their proteases in extravascular fibrinolysis. Semin. Thromb. Hemost., 1996, 22, 497-501.
14. Hu K.Q., Yu C.H., Vierling J.M.: Direct detection of circulating hepatitis C virus RNA using probes from the 5' untranslated region. J. Clin. Invest., 1992, 89, 2040-2045.
15. Inuzuka S. i wsp.: The significance of colocalization of plasminogen activator inhibitor-1 and vitronectin in hepatic fibrosis. Scand. J. Gastroenterol., 1997, 32, 1052-1060.
16. Kasprzak A. i wsp.: Obraz histopatologiczny, ekspresja HBV w tkance oraz wybrane dane kliniczne u dzieci chorych na przewlekle zapalenie wa̧troby typu B. Hepatol. Pol., 1999, 6, 115-122.
17. Kato N. i wsp.: Quantification of hepatitis C virus by competitive reverse transcription-polymerase chain reaction, increase of the virus in advanced liver disease. Hepatology, 1993, 18, 16-20.
18. Kato S., Kawasaki H.: Blood coagulation and fibrinolysis in relation to endotoxemia in liver cirrhosis and hepatocellular carcinoma. Nippon Shokakibyo Gakkai Zasshi, 1995, 92, 1143-1148 (streszczenie).
19. Leiper K. i wsp.: Tissue plasminogen activator, plasminogen activator inhibitors and activator-inhibitor complex in liver disease. J. Clin. Pathol., 1994, 47, 214-217.
20. Li Q., Qin C., Lao P.: Expression and plasma activity of plasminogen activator inhibitor-1 infibrotic liver tissues. Zhonghua Gan Zang Bing Za Zhi. 2000, 8, 209-211 (streszczenie).
21. Mackiewicz A. i wsp.: Complex of soluble human IL-6-receptor/IL-6 up-regulates expression of acute-phase proteins. J. Immunol., 1992, 149, 2021-2027.
22. Mammen E.F.: Coagulation defects in liver disease. Med. Clin. North Am., 1994, 78, 545-554.
23. Notoya A. i wsp.: Subclinical alterations in coagulation and fibrinolysis in patients undergoing autologous peripheral blood stem cell transplantation. Leuk. Lymphoma, 1998, 28, 405-413.
24. Paramo J.A. i wsp.: Thrombin activation and increased fibrinolysis in patients with chronic liver disease. Fibrinolysis, 1991, 2, 227-230.
25. Paramo J.A. i wsp.: Increased concentrations of tumor necrosis factor and interleukin-6 contribute to the hemostatic abnormalities in advanced liver disease. Haemostasis, 1995, 25, 305-311.
26. Pia̧tkowska M., Kotschy M., Halota W.: Wybrane parametry układu fibrynolizy we krwi chorych na marskość wa̧troby. Acta Haematol. Pol., 1996, 27, 403-409.
27. Ploplis V.A., Castellino F.J.: Nonfibrinolytic functions of plasminogen. Methods, 2000, 21, 103-110.
28. Rodriguez-Inigo E. i wsp.: Histological damage in chronic hepatitis C is not related to the extent of infection in the liver. AJP, 1999, 154, 1877-1881.
29. Segal H. i wsp.: Coagulation and fibrinolysis in primary biliary cirrhosis compared with other liver disease and during orthotopic liver transplantation. Hepatology, 1997, 25, 683-688.
30. Seki T. i wsp.: Production of tissue-type plasminogen activator (t-PA) and type-1 plasminogen activator inhibitor (PAI-1) in mildly cirrhotic rat liver. Thromb. Haemost., 1996, 75, 801-807.
31. Takada A., Takada Y., Urano B.: The physiological aspects of fibrinolysis. Thromb. Res., 1994, 76, 1-31.
32. Triger D.R.: Endotoksemia in liver diseases, time for reappraisal. J. Hepatol., 1991, 12, 136-142.
33. Vukovich T. i wsp.: Hemostasis activation in patients with liver cirrhosis. Thromb Res. 1995, 77, 271-278.
34. Wada Y. i wsp.: Effect of gabexate mesilate on thrombin and plasmin generation after hepatic resection in cirrhotic patients. Eur. Surg. Res., 1995, 27, 57-62.
35. Yuki N., Hayashi N., Kamada T.: HCV viraemia and liver injury in symptom-free blood donors (letter). Lancet, 1993, 342, 444.